The stock of Aratana Therapeutics Inc (NASDAQ:PETX) is a huge mover today! About 416,303 shares traded hands. Aratana Therapeutics Inc (NASDAQ:PETX) has risen 23.68% since April 14, 2016 and is uptrending. It has outperformed by 18.99% the S&P500.
The move comes after 5 months negative chart setup for the $277.09 million company. It was reported on Nov, 16 by Barchart.com. We have $6.73 PT which if reached, will make NASDAQ:PETX worth $27.71M less.
Aratana Therapeutics Inc (NASDAQ:PETX) Ratings Coverage
Out of 6 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Aratana Therapeutics has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Lake Street initiated the shares of PETX in a report on Wednesday, July 29 with “Buy” rating. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) has “Buy” rating given on Friday, August 19 by Jefferies. The rating was initiated by Credit Suisse with “Outperform” on Thursday, February 4. On Thursday, August 11 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, March 16. The stock has “Hold” rating given by Craig Hallum on Friday, September 25.
According to Zacks Investment Research, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.”
Insitutional Activity: The institutional sentiment increased to 1.59 in Q2 2016. Its up 0.47, from 1.12 in 2016Q1. The ratio improved, as 11 funds sold all Aratana Therapeutics Inc shares owned while 21 reduced positions. 12 funds bought stakes while 39 increased positions. They now own 30.25 million shares or 0.77% less from 30.49 million shares in 2016Q1.
Alpinvest Ptnrs Bv holds 1.25% or 100,001 shares in its portfolio. Blackrock Limited Liability has 125,058 shares for 0% of their US portfolio. Wellington Mgmt Group Ltd Liability Partnership last reported 1.15M shares in the company. Next Gp has 350 shares for 0% of their US portfolio. Jennison Associate Ltd holds 0.02% or 2.86 million shares in its portfolio. Wells Fargo Co Mn last reported 0% of its portfolio in the stock. Nationwide Fund Advisors owns 51,746 shares or 0% of their US portfolio. Metropolitan Life Com New York has invested 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX). Price T Rowe Associates Md holds 102,601 shares or 0% of its portfolio. Mpm Asset Management Ltd Liability Corporation accumulated 1.12 million shares or 2.29% of the stock. Vanguard accumulated 0% or 1.27 million shares. New York State Common Retirement Fund holds 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 29,100 shares. The Florida-based Raymond James Service Advsrs has invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). Tocqueville Asset Mgmt Limited Partnership last reported 0% of its portfolio in the stock. Rhumbline Advisers owns 33,189 shares or 0% of their US portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 5 insider sales for $1.57 million net activity. 100,000 shares with value of $626,313 were sold by St Peter Steven on Thursday, June 16. 30,000 shares with value of $277,599 were sold by TOOMAN CRAIG A on Friday, September 9. Another trade for 10,000 shares valued at $100,006 was sold by HEINEN ERNST.
More notable recent Aratana Therapeutics Inc (NASDAQ:PETX) news were published by: Fool.com which released: “How Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August” on September 09, 2016, also Prnewswire.com with their article: “Aratana Therapeutics Reports Second Quarter 2016 Financial Results” published on August 04, 2016, Prnewswire.com published: “Aratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit” on September 21, 2016. More interesting news about Aratana Therapeutics Inc (NASDAQ:PETX) were released by: Nasdaq.com and their article: “Earnings Reaction History: Aratana Therapeutics, Inc., 50.0% Follow-Through …” published on November 04, 2016 as well as Prnewswire.com‘s news article titled: “Aratana Therapeutics Reports Third Quarter 2016 Financial Results” with publication date: November 03, 2016.
PETX Company Profile
Aratana Therapeutics, Inc., incorporated on December 1, 2010, is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Company’s product candidates also include AT-014 for dogs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.